NE 0501

Drug Profile

NE 0501

Latest Information Update: 09 Sep 2003

Price : $50

At a glance

  • Originator Neose Technologies
  • Class Phosphonic acids; Pyridines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Xenotransplant rejection

Most Recent Events

  • 21 Jul 1998 Discontinued - Preclinical for Xenotransplant rejection in USA (unspecified route)
  • 29 Dec 1995 Preclinical development for Xenotransplant rejection in USA (Unknown route)
  • 29 Dec 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top